Navigation Links
AVONEX in Medical News

First 10-year follow-up shows that treatment with AVONEX leads to long-term benefits in early multiple sclerosis patients

SEATTLE, WA April 30, 2009 Biogen Idec (NASDAQ: BIIB) today announced data results from the CHAMPIONS (Controlled High-Risk AVONEX (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subj...

First ten-year follow-up shows that treatment with AVONEX leads to long-term benefits in early multiple sclerosis patients

SEATTLE, WA April 30, 2009 Biogen Idec (NASDAQ: BIIB) today announced data results from the CHAMPIONS (Controlled High-Risk AVONEX (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subj...

New data show patients using avonex reported less sick leave and short-term disability costs

Denver, CO June 2, 2008 Results from an analysis assessing the differences in health benefits costs (HBCs) and lost time among employees suffering from multiple sclerosis (MS) being treated with injectable disease modifying therapies (DMTs) were presented and announced by Biogen Idec as poster p...

MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR

... with 79 percent managed and 21 percent non-managed. The median age was 46 years and the majority was female. More than one-third of the patients used avonex as index medication, while others used Copaxone (31 percent), Rebif (17 percent), Betaseron (14 percent) and Tysabri (less than 1 percent). Abou...

Study shows that high-dose, high-frequency interferon produces no additional benefit

...V, open label, head-to-head study of intramuscular avonex and high-dose, high-frequency subcutaneous Rebif (...and Retrospective Long-Term Observational Study of avonex and Rebif (PROOF), involved 217 patients with 136 completing a median of 25.9 months of avonex 30 mcg once weekly (n=69) and a median of 22.2 mon...

New Data Suggests Progression of Disability at Two Years Predicts Multiple Sclerosis (MS) Disability Progression at Eight Years

...(RRMS). The analysis suggests that patients taking avonex for two years were less likely to experience disab...atment (81 placebo, 79 interferon beta-1a), in the avonex Phase III trial and who were re-examined eight yea...ysis revealed: -- Patients initially treated with avonex were less likely than patients initially recei...

Multiple Sclerosis Patients to Benefit With AVONEX(R) Nurse Services Program

...," said Marie Stallbaum, RN, BSN, a nurse with the avonex Nurse Services Program. "Nurses in this program wi...fullest and most active lives possible." The avonex Nurse Services program will have registered nurses...side effects ?Valuable phone counseling "The avonex Nurse Services program is the latest example of ou...
AVONEX in Medical Technology

New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 13, 2007 - Biogen Idec Inc. (NASDAQ: BIIB) announced today that one-year data presented at the Academy of Managed Care Pharmacy's (AMCP) 2007 Annual Meeting show that AVONEX(R) (Interferon beta-1a) is a cost-effective therapy in multiple sclerosis (MS) when co...

Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line

...patients. "Surveyed neurologists' responses suggest that Biogen Idec's avonex is more at-risk than Teva's Copaxone of losing share upon the launch of either oral cladribine or fingolimod, as more physicians cite avonex as having potential for being replaced by either emerging oral agent," stat...
AVONEX in Biological Technology

Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning

...e Officer of Tengion. "Mark brings extensive experience and a proven track record in both large pharma and biotech, including the successful launch of avonex for multiple sclerosis. His broad expertise in managing commercial activities across all stages of product development, and in specialty markets, will...

Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis

...est in first-line therapy. "The low volume of patient share attributed to avonex or Rebif compared with Copaxone in first- and second-line treatment illustr...h-dose, high-frequency agent reaches patient shares close to and surpassing avonex in first- and second-line treatment, respectively." According to the new ...

Olympics of biotechnology has international flavor

...cer. 1991 : Genzyme's Ceredase is approved by the FDA to treat Gaucher's disease and had 2006 sales of over $1 billion. 1996 : Biogen's drug avonex for multiple schlerosis is approved by the FDA, also with sales of over $1 billion annually. 2003 : The Broad Institute founded in Cambridge to g...
Other Tags
(Date:9/30/2014)... 2014 From October 12-15, MMS, ... the 2014 SHSMD Connections Annual Conference in San Diego, ... & Market Development (SHSMD) is proud to host the ... and communications, and strategic planning professionals in San Diego ... , The conference is a four-day event designed ...
(Date:9/30/2014)... IN (PRWEB) September 30, 2014 ... Ron Receveur encourages all persons who have received dental ... in a recent blog post. , The post, which ... with dental implants that if they don’t brush and ... same way people lose their natural teeth: the bone ...
(Date:9/30/2014)... “Biology and botany are having an ... it’s about naming rights.” , In Homeostasis: ... the Bryan William Brickner Blog, the focus is ... Health (PubMed). The post highlights five cannabinoid system ... aging with THC, the wake-inducing effects of CBD, ...
(Date:9/30/2014)... September 30, 2014 Named a ... East Longmeadow facility has officially announced that they ... that combines advanced medical technology with supportive, ... one of the only non-hospital options available in ... The primary focus of this Ventilator Program ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 American Medical ... a collaborative agreement to raise awareness about Alzheimer’s disease ... IDs for people with these brain disorders. , American ... generated by AFA to the foundation to support its ... their families. The ID bracelets and necklaces can be ...
Breaking Medicine News(10 mins):Health News:MMS, Inc. (Medical Marketing Service) to Attend the 2014 SHSMD Connections Annual Conference in October 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 3Health News:American Medical ID and Alzheimer’s Foundation of America Team up to Increase Awareness about Alzheimer’s Disease and Related Dementias 2Health News:American Medical ID and Alzheimer’s Foundation of America Team up to Increase Awareness about Alzheimer’s Disease and Related Dementias 3
(Date:9/28/2014)... findings by scientists at the University of California, Santa ... elements within the genomes of primates drove the evolution ... genes in every cell of our bodies. , ... as "retrotransposons" (a.k.a. "jumping genes") and the genes that ... researchers have, for the first time, identified genes in ...
(Date:9/27/2014)... expression levels of an enzyme involved in DNA synthesis ... certain treatments, a Korean study has shown at the ... phase II study, researchers showed that patients whose lung ... synthase experienced a greater benefit from treatment with the ... expressed high levels. , "Thymidylate synthase is one ...
(Date:9/27/2014)... and body mass in patients with advanced lung cancer ... phase III data presented at the ESMO 2014 Congress ... are among the most troubling and distressing symptoms of ... the study,s principal investigator, Dr Jennifer Temel from the ... Symptoms of the wasting syndrome can include a loss ...
Breaking Biology News(10 mins):Human genome was shaped by an evolutionary arms race with itself 2Human genome was shaped by an evolutionary arms race with itself 3Human genome was shaped by an evolutionary arms race with itself 4Customising chemotherapy in Lu Ca: New Ph II data reported in 2 LB studies 2Customising chemotherapy in Lu Ca: New Ph II data reported in 2 LB studies 3Customising chemotherapy in Lu Ca: New Ph II data reported in 2 LB studies 4Anamorelin improve appetite and body mass in patients with cancer anorexia-cachexia 2Anamorelin improve appetite and body mass in patients with cancer anorexia-cachexia 3Anamorelin improve appetite and body mass in patients with cancer anorexia-cachexia 4
Other Contents